Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.

George T Kannarkat, Stanley N Caroff, James F Morley

Tremor and other hyperkinetic movements (New York, N.Y.) 2022

filter terms:

The last decade has seen development of numerous novel antipsychotic drugs with unique mechanisms including long-acting formulations for clinical use. A comparative assessment of these new drugs with each other and previous antipsychotics have not been performed with regards to risk for drug-induced movement disorders (DIMD). Medline was searched from January 2010 to February 2022 for primary research articles and review articles in English using the search terms "extrapyramidal" and "tardive" with individual drug names of novel antipsychotics. We identified articles describing the risk of DIMD with 6 novel antipsychotics, 4 novel formulations, and 3 experimental antipsychotics. Both short- and long-term data generally showed comparable to lower risk of DIMD with novel antipsychotics and recent long-acting formulations compared to previously marketed antipsychotics. Several novel antipsychotics, particularly lumateperone and pimavanserin, show promise in being able to treat psychosis while reducing the risk of DIMD. Long-acting paliperidone may reduce risk of DIMD while other long-acting injectable formulations of SGA have similar risk of DIMD compared to oral formulations. New drug targets for treating psychosis without dopamine blockade also show promise. Copyright: © 2022 The Author(s).

Citation

George T Kannarkat, Stanley N Caroff, James F Morley. Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and other hyperkinetic movements (New York, N.Y.). 2022;12:19